(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
Recruiting
N/A
Interventional Study
Epiretinal Membrane
Dry Age Related Macular Degeneration
Macular Abnormalities
Retina Disease
Vitreoretinal Abnormality
Intraretinal Hyporeflective Space
Subretinal Hyporeflective Space
IS/OS (Ellipsoid Zone) Disruption
Retinal Pigment Epithelium (RPE) Elevation
Retinal Pigment Epithelium (RPE) Atrophy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 400 (estimated)
- Sponsor
- Carl Zeiss Meditec-Dublin CoCe · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Able and willing to make the required study visits.
2. Able and willing to give written informed consent and follow study instructions.
3. Able and willing to complete ophthalmic imaging.
4. Adults 18 years of age or older.
The subject population will be comprised of two gro…
Contacts